Form 4: Veracyte Executive Sells Shares Under 10b5-1 Plan

Veracyte's SVP and General Counsel, Annie McGuire, sold 6,658 shares of common stock for approximately $236,770 through a pre-arranged 10b5-1 plan.

Summary

• Annie McGuire, SVP, General Counsel of Veracyte, Inc. (VCYT), reported sales of common stock.
• The transactions occurred on March 4, 2026.
• A total of 6,658 shares were sold in two separate transactions.
• The first sale involved 4,994 shares at a weighted average price of $35.2936 per share.
• The second sale involved 1,664 shares at a weighted average price of $36.3393 per share.
• These sales were executed under a Rule 10b5-1 plan adopted on August 29, 2025.
• Following these transactions, Annie McGuire beneficially owns 94,706 shares of Veracyte common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event because the sales were conducted under a pre-arranged 10b5-1 plan, which typically indicates personal financial planning rather than a change in the executive's outlook on the company.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces the insider's direct stake in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales under a 10b5-1 plan are common for executives to manage personal finances and diversify holdings, often pre-scheduled to avoid accusations of trading on material non-public information. This type of transaction is typical across various industries, including biotechnology and diagnostics, where executive compensation often includes equity.

Comparison to Industry Standards

• Insider sales are a standard practice for executives across all industries, including biotech and diagnostics.
• Companies like Illumina or Guardant Health also see executives utilize 10b5-1 plans for similar purposes.
• The volume of shares sold by Ms. McGuire represents a relatively small percentage of her total holdings, which is consistent with typical diversification strategies rather than a significant divestment.

Stakeholder Impact

• Shareholders: May interpret insider selling as a slight negative, though mitigated by the 10b5-1 plan.

Key Dates

Recommendation

The insider sale, executed under a pre-arranged 10b5-1 plan, is a routine event for executive compensation and personal financial management. It does not provide new material information to warrant a change in investment thesis, thus a "hold" recommendation is appropriate.

Keywords

Veracyte, VCYT, Insider Trading, Form 4, Stock Sale, Annie McGuire, 10b5-1 Plan, Biotechnology, Diagnostics